FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
Betsy Goodfellow | February 14, 2024 | News story | Medical Communications | FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (Nalirifox) as a first line treatment for adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
This approval is the second for an Onivyde regimen in mPDAC, following one in 2015 for Onivyde plus fluorouracil and leucovorin following disease progression with gemcitabine-based therapy.
Christelle Huguet, EVP and head of research and development at Ipsen, commented: “The results from the phase 3 NAPOLI 3 trial represent the first positive data for an investigational regimen in first-line metastatic pancreatic adenocarcinoma versus the currently approved nab-paclitaxel and gemcitabine regimen. With today’s approval, this Onivyde (Nalirifox) regimen can now offer a potential new standard-of-care treatment option with proven survival benefits for people living with metastatic pancreatic adenocarcinoma in the US.”
Dr Zev Wainberg, professor of medicine and co-director of the UCLA GI Oncology Programme, added: “Metastatic pancreatic adenocarcinoma is a difficult disease to manage with very few available treatment options. Given the reality of this aggressive form of cancer and the complexity of the disease, every advance in the treatment landscape represents a meaningful improvement in patient outcomes. The approval of this Onivyde regimen is an important milestone for people living with mPDAC, their families and healthcare providers, with the NAPOLI 3 trial having demonstrated survival benefits versus a current standard of care treatment option.”
Betsy Goodfellow
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
